vascular endothelial growth factor antagonists
Binds to and inactivates Vascular Endothelial Growth Factor (VEGF) receptors which normally promote neovascularization and vascular permeability.
Absorption: Action is local following intravitreal injection, minimal systemic absorption occurs.
Distribution: Distribution occurs mainly in the vitreal space.
Metabolism and Excretion: Used up in the binding process and degraded by proteolytic enzymes.
Half-life: 5–6 days (plasma).
TIME/ACTION PROFILE (improved visual acuity)
|intravitreal||rapid (within 4 wk)||8–12 wk||maintained throughout treatment|
Ocular/periocular infectionActive intraocular inflammation
Use Cautiously in:
CV: MI, STROKE
EENT: conjunctival hemorrhage, eye pain, blurred vision, cataract, corneal edema, corneal erosion, conjunctival hyperemia, detachment of retinal pigment epithelium, endophthalmitis (from procedure), eyelid edema, foreign body sensation, injection site hemorrhage/pain, intraocular inflammation, ↑ intraocular pressure, ↑ lacrimation, retinal detachment (from procedure), vitreous detachment, vitreous floaters
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Neovascular (Wet) AMD
Intravitreal (Adults): 2 mg every 4 wk for first 12 wk, then 2 mg every 8 wk (some patients may continue to require every 4 wk dosing). After one year of therapy, may consider dosing every 12 wk.
Macular Edema Following CRVO
Intravitreal (Adults): 2 mg every 4 wk.
Diabetic Macular Edema and Diabetic Retinopathy
Intravitreal (Adults): 2 mg every 4 wk for first 5 injections, then 2 mg every 8 wk (some patients may continue to require every 4 wk dosing).
Solution for injection: 2 mg/0.05 mL
Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Complete Product Information.